Association Between Anti-Hepatitis C Viral Intervention Therapy and Risk of Sjögren's Syndrome: A National Retrospective Analysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Jul 27

PMID 35893350

Authors

Chien-Hsueh Tung

Yen-Chun Chen

Yi-Chun Chen

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) infection is a potential risk factor for Sjögren's syndrome (SS). However, it is unclear whether anti-HCV intervention therapy could decrease SS risk. A retrospective cohort analysis from 1997-2012 comprising 17,166 eligible HCV-infected adults was conducted. By 1:2 propensity score matching, a total of 2123 treated patients and 4246 untreated patients were subjected to analysis. The incidence rates and risks of SS and death were evaluated through to the end of 2012. In a total follow-up of 36,906 person-years, 177 (2.8%) patients developed SS, and 522 (8.2%) died during the study period. The incidence rates of SS for the treated and untreated cohorts were 5.3 vs. 4.7/1000 person-years, and those of death for the treated and untreated cohorts were 10.0 vs. 14.8/1000 person-years. A lower risk of death (adjusted hazard ratio, 0.68; 95% CI, 0.53-0.87) was present in HCV-infected patients receiving anti-HCV therapy in multivariable Cox regression, and this remained consistent in multivariable stratified analysis. However, there were no relationships between anti-HCV therapy and its therapeutic duration, and SS risk in multivariable Cox regression. In conclusion, anti-HCV intervention therapy was not associated with lower SS risk in HCV-infected patients, but associated with lower death risk.

Citing Articles

A comprehensive review of Sjögren's syndrome: Classification criteria, risk factors, and signaling pathways.

Zhao T, Zhang R, Li Z, Qin D, Wang X Heliyon. 2024; 10(17):e36220.

PMID: 39286095 PMC: 11403439. DOI: 10.1016/j.heliyon.2024.e36220.

Hepatitis C Epidemiology: Insights from a Comprehensive Cohort Study in ASST Melegnano and Martesana, Lombardia Region, Northern Italy.

Nardone M, Di Stasio D, Lucchese A, Gentili D, Cattabianchi G, Signorelli C Pathogens. 2024; 13(3).

PMID: 38535558 PMC: 10974120. DOI: 10.3390/pathogens13030215.

Salivary Glands and Viral Pathogenesis.

Atyeo N, Maldonado J, Warner B, Chiorini J J Dent Res. 2024; 103(3):227-234.

PMID: 38344753 PMC: 10985391. DOI: 10.1177/00220345231222871.

Current Views on Pathophysiology and Potential Therapeutic Targets in Sjögren's Syndrome: A Review from the Perspective of Viral Infections, Toll-like Receptors, and Long-Noncoding RNAs.

Horai Y, Shimizu T, Umeda M, Nishihata S, Nakamura H, Kawakami A J Clin Med. 2023; 12(18).

PMID: 37762814 PMC: 10531551. DOI: 10.3390/jcm12185873.

Sjögren's syndrome.

Balint G, Buchanan W, Kean C, Kean W, Rainsford K Inflammopharmacology. 2023; 32(1):37-43.

PMID: 37195497 DOI: 10.1007/s10787-023-01222-z.

References

Carrillo-Ballesteros F, Palafox-Sanchez C, Franco-Topete R, Munoz-Valle J, Orozco-Barocio G, Martinez-Bonilla G . Expression of BAFF and BAFF receptors in primary Sjögren's syndrome patients with ectopic germinal center-like structures. Clin Exp Med. 2020; 20(4):615-626. DOI: 10.1007/s10238-020-00637-0. View

Sun Y, Chang Y, Chen H, Su Y, Su H, Li C . Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care. 2012; 35(5):1047-9. PMC: 3329814. DOI: 10.2337/dc11-1511. View

Chen Y, Su Y, Li C, Wu C, Lee M . A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int. 2014; 87(5):1030-8. DOI: 10.1038/ki.2014.363. View

Cheng J, Lin Y, Hu J, Chang M, Ku H, Chien R . Impact of Interferon-Based Therapy on Hepatitis C-Associated Rheumatic Diseases: A Nationwide Population-Based Cohort Study. J Clin Med. 2021; 10(4). PMC: 7922671. DOI: 10.3390/jcm10040817. View

Li X, Xu B, Ma Y, Li X, Cheng Q, Wang X . Clinical and laboratory profiles of primary Sjogren's syndrome in a Chinese population: A retrospective analysis of 315 patients. Int J Rheum Dis. 2015; 18(4):439-46. DOI: 10.1111/1756-185X.12583. View

Yeh C, Wang W, Wu C, Sung F, Su C, Shieh Y . Association of Sjögrens Syndrome in Patients with Chronic Hepatitis Virus Infection: A Population-Based Analysis. PLoS One. 2016; 11(8):e0161958. PMC: 4999293. DOI: 10.1371/journal.pone.0161958. View

Doffoel-Hantz V, Loustaud-Ratti V, Ramos-Casals M, Alain S, Bezanahary H, Liozon E . [Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin]. Rev Med Interne. 2005; 26(2):88-94. DOI: 10.1016/j.revmed.2004.10.020. View

Toussirot E, Le Huede G, Mougin C, Balblanc J, Bettinger D, Wendling D . Presence of hepatitis C virus RNA in the salivary glands of patients with Sjögren's syndrome and hepatitis C virus infection. J Rheumatol. 2002; 29(11):2382-5. View

De Maeyer E, De Maeyer-Guignard J . Type I interferons. Int Rev Immunol. 1999; 17(1-4):53-73. DOI: 10.3109/08830189809084487. View

10.

Shiboski S, Shiboski C, Criswell L, Baer A, Challacombe S, Lanfranchi H . American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012; 64(4):475-87. PMC: 3349440. DOI: 10.1002/acr.21591. View

11.

Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y . Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun. 2006; 27(2):134-9. DOI: 10.1016/j.jaut.2006.07.005. View

12.

Verbaan H, Carlson J, Eriksson S, Larsson A, Liedholm R, Manthorpe R . Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients. J Intern Med. 1999; 245(2):127-32. DOI: 10.1046/j.1365-2796.1999.00414.x. View

13.

Zignego A, Giannini C, Gragnani L . HCV and lymphoproliferation. Clin Dev Immunol. 2012; 2012:980942. PMC: 3407626. DOI: 10.1155/2012/980942. View

14.

Scott C, Avellini C, Desinan L, Pirisi M, Ferraccioli G, Bardus P . Chronic lymphocytic sialoadenitis in HCV-related chronic liver disease: comparison of Sjögren's syndrome. Histopathology. 1997; 30(1):41-8. DOI: 10.1046/j.1365-2559.1997.d01-561.x. View

15.

Vakaloglou K, Mavragani C . Activation of the type I interferon pathway in primary Sjögren's syndrome: an update. Curr Opin Rheumatol. 2011; 23(5):459-64. DOI: 10.1097/BOR.0b013e328349fd30. View

16.

Lu M, Yin W, Tsai T, Koo M, Lai N . Increased risk of primary Sjögren's syndrome in female patients with thyroid disorders: a longitudinal population-based study in Taiwan. PLoS One. 2013; 8(10):e77210. PMC: 3799635. DOI: 10.1371/journal.pone.0077210. View

17.

Ramos-Casals M, Munoz S, Zeron P . Hepatitis C virus and Sjögren's syndrome: trigger or mimic?. Rheum Dis Clin North Am. 2008; 34(4):869-84, vii. DOI: 10.1016/j.rdc.2008.08.007. View

18.

Potthoff A, Witte T, Rifai K, Hoy L, Deterding K, Feyerabend S . Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjögren syndrome. Scand J Gastroenterol. 2009; 44(8):994-1003. DOI: 10.1080/00365520902929864. View

19.

Coll J, Gambus G, Corominas J, Tomas S, Esteban J, Guardia J . Immunohistochemistry of minor salivary gland biopsy specimens from patients with Sjögren's syndrome with and without hepatitis C virus infection. Ann Rheum Dis. 1997; 56(6):390-2. PMC: 1752393. DOI: 10.1136/ard.56.6.390. View

20.

Heo N, Lim Y, Lee H, Lee Y, Kim K, Byun K . High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. Clin Mol Hepatol. 2013; 19(1):60-9. PMC: 3622857. DOI: 10.3350/cmh.2013.19.1.60. View